keyword
https://read.qxmd.com/read/38829416/long-term-safety-and-effectiveness-of-rituximab-biosimilar-rtxm83-a-retrospective-extension-study-in-brazilian-patients-with-diffuse-large-b-cell-lymphoma
#1
JOURNAL ARTICLE
Marcia Torresan Delamain, Ana Carolina Ferreira Cardoso, Fernando Vieira Pericole, Sérgio Shusterschitz da Silva Araújo, Laura Fogliatto, Marcia Higashi, Juliana Pereira, Roberto Luiz da Silva, Gustavo Werutsky, Patrícia de Paulo Giacon Radtke, Marco Aurélio Salvino, Vivienne Castilho
INTRODUCTION: RTXM83, a biosimilar of rituximab, was approved after physicochemical, functional, non-clinical, and clinical studies demonstrated their similarity; these studies included RTXM83-AC-01-11, a multicentric double-blind international prospective pivotal study. Long-term data on biosimilars can potentially elucidate their clinical robustness and facilitate their broader adoption. METHODS: In this retrospective observational study, we analyzed a dataset from a Brazilian cohort previously randomized in the RTXM83-AC-01-11 study followed by the assessment of long-term outcomes in an observational extension phase from randomization in the RTXM83-AC-01-11 study to the last recorded evaluation...
June 3, 2024: Oncology and Therapy
https://read.qxmd.com/read/38827343/thymoquinone-nanoparticle-induces-apoptosis-and-cell-migration-retardation-through-modulating-of-sumoylation-process-genes-in-breast-cancer-cell-line
#2
JOURNAL ARTICLE
Behnoush Sohrabi, Mohaddese Qadbeigi, Farzaneh Sabouni, Ahmad Hamta
BACKGROUND: Due to the heterogeneity of breast cancer, most advanced-stage patients are resistant to therapy. Disruption of SUMOylation, a post-translational modification, is linked to breast cancer. OBJECTIVE: This study aimed to assess the impact of thymoquinone nanoparticles (Liposomal-TQ), an anti-cancer drug, combined with doxorubicin (DXR), the most effective chemotherapeutic drug used to treat breast cancer, on the expression of SENP2 and SENP6, two major components involved in the SUMOylation process, in normal and cancerous breast cell lines...
January 2024: Iranian Journal of Biotechnology
https://read.qxmd.com/read/38825303/ibrutinib-a-bruton-s-tyrosine-kinase-inhibitor-regulates-ventricular-electromechanical-activities-and-enhances-arrhythmogenesis
#3
JOURNAL ARTICLE
Chih-Min Liu, Fong-Jhih Lin, Chheng Chhay, Yao-Chang Chen, Yung-Kuo Lin, Yen-Yu Lu, Chao-Shun Chan, Satoshi Higa, Shih-Ann Chen, Yi-Jen Chen
BACKGROUND: Ibrutinib, a Bruton's tyrosine kinase inhibitor used in cancer therapy, exerts ventricular proarrhythmic effects; however, the underlying mechanisms remain unclear. Excitation-contraction coupling (E-C) disorders are pivotal for the genesis of ventricular arrhythmias (VAs), which arise mainly from the right ventricular outflow tract (RVOT). In this study, we aimed to comprehensively investigate whether ibrutinib regulates the electromechanical activities of the RVOT, leading to enhanced arrhythmogenesis, and explore the underlying mechanisms...
May 31, 2024: European Journal of Pharmacology
https://read.qxmd.com/read/38824813/proton-therapy-re-irradiation-outcomes-and-genomic-landscape-of-patients-with-recurrent-head-and-neck-cancer
#4
JOURNAL ARTICLE
Rebecca Krc, William Mendes, Jason Molitoris, Matthew Ferris, Yang Song, Amol Shetty, Ranee Mehra, John C Papadimitriou, Kyle Hatten, Rodney Taylor, Jeffrey Wolf, Kai Sun, Soren Bentzen, William Regine, Phuoc Tran, Matthew Witek
INTRODUCTION: Re-irradiation (re-RT) for recurrent head and neck cancer (rHNC) is challenging. We describe clinical outcomes and toxicity of proton therapy (PT) for recurrent HNC, and report genomic alterations associated with patterns of failure. MATERIALS & METHODS: We performed a retrospective analysis of rHNC patients treated with PT. Outcomes were estimated using the Kaplan-Meier method. Univariate (UVA) and multivariate analyses (MVA) were performed to assess multiple patient factors...
June 1, 2024: Oral Oncology
https://read.qxmd.com/read/38821626/deciphering-the-role-of-mir-30a-5p-and-dlgap1-gene-in-non-small-cell-lung-cancer
#5
JOURNAL ARTICLE
Weronika Świtlik, Zbigniew Wyżewski, Karolina Gregorczyk-Zboroch, Marta Gietler, Agnieszka Pudlarz, Joanna Szewińska, Sławomir Orzechowski, Sławomir Jakieła, Janusz Szemraj
BACKGROUND/AIM: Non-small cell lung cancer (NSCLC) is the deadliest form of cancer worldwide. Understanding the mechanisms of lung cancer development is vital for targeted therapy advancements. This article explores the little-known role of the guanylate kinase-associated protein (GKAP), encoded by the Disks large-associated protein 1 (DLGAP1) gene, in NSCLC along with assessing microRNA-30a-5p's influence on DLGAP1 gene expression in the A549 cell line. MATERIALS AND METHODS: Experiments were conducted on A549 cells transfected with synthetic oligonucleotides...
June 2024: Anticancer Research
https://read.qxmd.com/read/38821601/dna-binding-agent-trabectedin-combined-with-recombinant-methioninase-is-synergistic-to-decrease-fibrosarcoma-cell-viability-and-induce-nuclear-fragmentation-but-not-synergistic-on-normal-fibroblasts
#6
JOURNAL ARTICLE
Sei Morinaga, Qinghong Han, Yutaro Kubota, Kohei Mizuta, Byung Mo Kang, Motokazu Sato, Michael Bouvet, Norio Yamamoto, Katsuhiro Hayashi, Hiroaki Kimura, Shinji Miwa, Kentaro Igarashi, Takashi Higuchi, Hiroyuki Tsuchiya, Satoru Demura, Robert M Hoffman
BACKGROUND/AIM: The alkylating agent trabectedin, which binds the minor groove of DNA, is second-line therapy for soft-tissue sarcoma but has only moderate efficacy. The aim of the present study was to determine the synergistic efficacy of recombinant methioninase (rMETase) and trabectedin on fibrosarcoma cells in vitro, compared with normal fibroblasts. MATERIALS AND METHODS: HT1080 human fibrosarcoma cells expressing green fluorescent protein (GFP) in the nucleus and red fluorescent protein (RFP) in the cytoplasm and Hs27 normal human fibroblasts, were used...
June 2024: Anticancer Research
https://read.qxmd.com/read/38819452/phytofabrication-of-biocompatible-zinc-oxide-nanoparticle-using-gymnema-sylvestre-and-its-potent-in-vitro-antibacterial-antibiofilm-and-cytotoxicity-against-human-breast-cancer-cells-mda-mb-231
#7
JOURNAL ARTICLE
R Kavipriya, R Ramasubburayan
The increasing incidence of breast cancer and bacterial biofilm in medical devices significantly heightens global mortality and morbidity, challenging synthetic drugs. Consequently, greener-synthesized nanomaterials have emerged as a versatile alternative for various biomedical applications, offering new therapeutic avenues. This study explores the synthesis of biocompatible zinc oxide (ZnONPs) nanoparticles using Gymnema sylvestre and its antibacterial, antibiofilm, and cytotoxic properties. Characterization of ZnONPs inferred that UV-Vis spectra exhibited a sharp peak at 370 nm...
May 31, 2024: Bioprocess and Biosystems Engineering
https://read.qxmd.com/read/38817995/biomarker-in-hepatocellular-carcinoma
#8
REVIEW
Pooja Basthi Mohan, Rajiv Lochan, Shiran Shetty
Liver cancer is one of the most prevalent types of cancer and a major contributor to the socioeconomic burden worldwide. The pathogenesis of hepatocellular carcinoma (HCC) is contributed by various etiological factors like virus infection, excessive alcohol consumption, exposure to toxins, or metabolic disorders. Majority of patients are diagnosed with late-stage HCC, which restricts its management to only palliative care. HCC, if diagnosed early, increases the survival and quality of life. Currently available biomarker (alpha-fetoproteins) have several limitations, that impede the early diagnosis and staging of cancer...
May 2024: Indian Journal of Surgical Oncology
https://read.qxmd.com/read/38814482/outcomes-of-definitive-carbon-ion-radiotherapy-for-ct1bn0m0-esophageal-squamous-cell-carcinoma
#9
JOURNAL ARTICLE
Tetsuro Isozaki, Hitoshi Ishikawa, Shigeru Yamada, Yoshihiro Nabeya, Keiko Minashi, Kentaro Murakami, Hisahiro Matsubara
BACKGROUND: A recent phase I/II study determined the optimal dose of definitive carbon-ion radiotherapy (CIRT) for cT1bN0M0 esophageal cancer. This study aimed to further confirm the efficacy and feasibility of the recommended dose fractionation of CIRT with long-term follow-up results in a larger sample size. METHODS: This single center retrospective study evaluated patients with cT1bN0M0 esophageal squamous cell carcinoma treated with the recommended dose fractionation of 50...
May 30, 2024: Esophagus: Official Journal of the Japan Esophageal Society
https://read.qxmd.com/read/38803531/efficacy-and-safety-of-stereotactic-radiotherapy-on-elderly-patients-with-stage-i-ii-central-non-small-cell-lung-cancer
#10
JOURNAL ARTICLE
Xiaoqin Ji, Bin Zhou, Hua Huang, Yong Wang, Wanrong Jiang, Jiasheng Wang, Wei Ding, Zhen Wang, Guanha Chen, Xiangdong Sun
BACKGROUND: Many studies demonstrated the safety and efficacy of SBRT in the treatment of elderly patients with early-stage non-small cell lung cancer (NSCLC). However, those studies focused on patients with peripheral lung cancer. This study aimed to evaluate the clinical efficacy and toxicity of SBRT in elderly patients with stage I-II central NSCLC in single institution. METHODS: From April 2009 to January 2020, a retrospective study was conducted on patients ≥ 65 years old with stage I-II NSCLC that was centrally localized and treated with SBRT at a single institution...
2024: Frontiers in Oncology
https://read.qxmd.com/read/38802747/long-term-follow-up-of-protective-effects-on-salivary-and-swallowing-structures-and-improvement-of-late-xerostomia-and-dysphagia-by-level-iib-optimisation-in-clinical-target-volume-of-nasopharyngeal-carcinoma
#11
JOURNAL ARTICLE
Jiawei Zhou, Li Wang, Ting Qiu, Han Gao, Lijun Wang, Shengfu Huang, Xia He, Lirong Wu
BACKGROUND: This study aimed to assess the long-term effect of level IIb clinical target volume (CTV) optimisation on survival, xerostomia, and dysphagia in patients with nasopharyngeal carcinoma (NPC). METHODS: Clinical data of 415 patients with NPC treated with intensity-modulated radiotherapy between December 2014 and October 2018 were retrospectively analysed. The patients were categorised into modified and comparison groups. Late xerostomia and dysphagia were evaluated using Radiation Therapy Oncology Group/European Organisation for Research and Treatment of Cancer scoring...
May 27, 2024: BMC Cancer
https://read.qxmd.com/read/38800387/using-an-mhealth-approach-to-collect-patient-generated-health-data-for-predicting-adverse-health-outcomes-among-adult-survivors-of-childhood-cancer
#12
JOURNAL ARTICLE
Kristen E Howell, Marian Shaw, Aimee K Santucci, Kristy Rodgers, Izeris Ortiz Rodriguez, Danah Taha, Sara Laclair, Carol Wolder, Christie Cooper, Wonjong Moon, Christopher Vukadinovich, Matthew J Erhardt, Shannon M Dean, Gregory T Armstrong, Kirsten K Ness, Melissa M Hudson, Yutaka Yasui, I-Chan Huang
INTRODUCTION: Cancer therapies predispose childhood cancer survivors to various treatment-related late effects, which contribute to a higher symptom burden, chronic health conditions (CHCs), and premature mortality. Regular monitoring of symptoms between clinic visits is useful for timely medical consultation and interventions that can improve quality of life (QOL). The Health Share Study aims to utilize mHealth to collect patient-generated health data (PGHD; daily symptoms, momentary physical health status) and develop survivor-specific risk prediction scores for mitigating adverse health outcomes including poor QOL and emergency room admissions...
2024: Frontiers in Oncology
https://read.qxmd.com/read/38792509/circulating-levels-of-soluble-%C3%AE-klotho-and-fgf23-in-childhood-cancer-survivors-lack-of-association-with-nephro-and-cardiotoxicity-a-preliminary-study
#13
JOURNAL ARTICLE
Kacper Kozłowski, Katarzyna Konończuk, Katarzyna Muszyńska-Rosłan, Beata Żelazowska-Rutkowska, Katarzyna Taranta-Janusz, Katarzyna Werbel, Maryna Krawczuk-Rybak, Eryk Latoch
Background/Objectives: The survival rate among pediatric cancer patients has reached 80%; however, these childhood cancer survivors (CCSs) are at a heightened risk of developing chronic conditions in adulthood, particularly kidney and cardiovascular diseases. The aims of this study were to assess the serum α-Klotho and FGF23 levels in CCSs and to determine their association with nephro- and cardiotoxicity. Methods: This study evaluated a cohort of 66 CCSs who remained in continuous remission, with a mean follow-up of 8...
May 17, 2024: Journal of Clinical Medicine
https://read.qxmd.com/read/38791188/natural-killer-cells-reprogram-myeloid-derived-suppressor-cells-to-induce-tnf-%C3%AE-release-via-nkg2d-ligand-interaction-after-cryo-thermal-therapy
#14
JOURNAL ARTICLE
Jiaqi You, Shicheng Wang, Yongxin Zhu, Zelu Zhang, Junjun Wang, Yue Lou, Yichen Yao, Yuankai Hao, Ping Liu
In our previous studies, a novel cryothermal therapy (CTT) was developed to induce systemic long-term anti-tumor immunity. Natural killer (NK) cells were found to play an important role in CTT-induced long-term immune-mediated tumor control at the late stage after CTT, but the underlying mechanism is unclear. Myeloid-derived suppressor cells (MDSCs) are immature myeloid cells that have potent immunosuppressive effects on T cells and weaken the long-term benefits of immunotherapy. Consequently, overcoming MDSC immunosuppression is essential for maintaining the long-term efficacy of immunotherapy...
May 9, 2024: International Journal of Molecular Sciences
https://read.qxmd.com/read/38790138/spliceosomic-dysregulation-in-pancreatic-cancer-uncovers-splicing-factors-prpf8-and-rbmx-as-novel-candidate-actionable-targets
#15
JOURNAL ARTICLE
Emilia Alors-Pérez, Ricardo Blázquez-Encinas, María Trinidad Moreno-Montilla, Víctor García-Vioque, Juan Manuel Jiménez-Vacas, Andrea Mafficini, Iranzu González-Borja, Claudio Luchini, Juan M Sánchez-Hidalgo, Marina E Sánchez-Frías, Sergio Pedraza-Arevalo, Antonio Romero-Ruiz, Rita T Lawlor, Antonio Viúdez, Manuel D Gahete, Aldo Scarpa, Álvaro Arjona-Sánchez, Raúl M Luque, Alejandro Ibáñez-Costa, Justo P Castaño
Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal cancer, characterized by late diagnosis and poor treatment response. Surgery is the only curative approach, only available to early-diagnosed patients. Current therapies have limited effects, cause severe toxicities, and minimally improve overall survival. Understanding of splicing machinery alterations in PDAC remains incomplete. Here, we comprehensively examined 59 splicing machinery components, uncovering dysregulation in pre-mRNA processing factor 8 (PRPF8) and RNA-binding motif protein X-linked (RBMX)...
May 24, 2024: Molecular Oncology
https://read.qxmd.com/read/38788449/car-t-cell-therapy-efficacy-in-management-of-cancers-adverse-effects-dose-limiting-toxicities-and-long-term-follow-up
#16
REVIEW
Mohamed Elmarasi, Islam Elkonaissi, Ahmed Adel Elsabagh, Engy Elsayed, Abdelrahman Elsayed, Basant Elsayed, Ibrahim Elmakaty, Mohamed Yassin
Chimeric Antigen Receptor T-cell (CAR-T) therapy has emerged as a groundbreaking and highly promising approach for the management of cancer. This paper reviews the efficacy of CAR-T therapy in the treatment of various hematological malignancies, also, with a mention of its effect on solid tumors, for which they have not received FDA approval yet. Different common and uncommon side effects are also discussed in this paper, with attention to the effect of each drug separately. By reviewing the recommendations of the FDA for CAR-T therapy research, we have extensively discussed dose-limiting toxicities...
May 23, 2024: International Immunopharmacology
https://read.qxmd.com/read/38788179/pediatric-and-adolescent-hodgkin-lymphoma-paving-the-way-for-standards-of-care-and-shared-decision-making
#17
REVIEW
Justine M Kahn, Christine Mauz-Korholz, Tricia Hernandez, Sarah A Milgrom, Sharon M Castellino
Hodgkin lymphoma (HL) is a treatable cancer with an incidence peak in adolescent and young adult years. Treatment strategies have been developed to balance the intensity of therapy needed to maintain disease-free survival while simultaneously preserving overall survival. Risk-based, response-adapted frontline therapy has long used a combination of chemotherapy and radiotherapy (RT). Successive clinical trials over the past three decades have safely reduced cumulative alkylator, anthracycline, and RT exposures for many patients...
June 2024: American Society of Clinical Oncology Educational Book
https://read.qxmd.com/read/38787491/physical-impairments-activity-limitations-and-participation-restrictions-of-childhood-acute-lymphoblastic-leukemia-survivors-with-and-without-hip-osteonecrosis-a-petale-cohort-study
#18
JOURNAL ARTICLE
Annie Brochu, Dahlia Kairy, Nathalie Alos, Caroline Laverdière, Daniel Sinnett, Serge Sultan, Daniel Curnier, Marie-Claude Miron, Ramy El-Jalbout, Melissa Fiscaletti, Luc J Hébert
PURPOSE: Long-term musculoskeletal complications represent a growing burden for survivors of childhood acute lymphoblastic leukemia (cALL). This study aimed to describe physical impairments, activity limitations, and participation restrictions in a high-risk subgroup of cALL survivors of the PETALE cohort. METHODS: This cross-sectional study, using observational data from the PETALE cohort, included a subgroup of survivors who presented high-risk criteria for late effects...
May 24, 2024: Journal of Cancer Survivorship: Research and Practice
https://read.qxmd.com/read/38787191/radiotherapy-for-canine-apocrine-gland-anal-sac-adenocarcinoma-survival-outcomes-and-side-effects-of-a-palliative-treatment-protocol-of-20-gy-in-five-consecutive-fractions
#19
JOURNAL ARTICLE
Carlos Roberto Mendez Valenzuela, Kelly Shin, Hsin-Yi Weng, Jeannie M Plantenga, Isabelle F Vanhaezebrouck
This research aims to evaluate the outcomes of a radiotherapy protocol, consisting of five fractions of 4 Gy each, resulting in a total dose of 20 Gy for apocrine gland anal sac tumors and local lymph nodes in canines. This protocol was assessed as a palliative treatment for macroscopic tumors alone, or in combination with additional therapies under different scenarios. Medical records from fifty canine patients met the inclusion criteria and were divided into different treatment groups: radiotherapy alone (n = 22, 44%), radiotherapy with chemotherapy or targeted therapy with toceranib (n = 18, 36%), surgery with radiotherapy (n = 5, 10%), and surgery with radiotherapy and chemotherapy or targeted therapy with toceranib (n = 5, 10%)...
May 15, 2024: Veterinary Sciences
https://read.qxmd.com/read/38784451/pyrazolopyridine-based-kinase-inhibitors-for-anti-cancer-targeted-therapy
#20
REVIEW
Pallabi Halder, Anubhav Rai, Vishal Talukdar, Parthasarathi Das, Naga Rajiv Lakkaniga
The need for effective cancer treatments continues to be a challenge for the biomedical research community. In this case, the advent of targeted therapy has significantly improved therapeutic outcomes. Drug discovery and development efforts targeting kinases have resulted in the approval of several small-molecule anti-cancer drugs based on ATP-mimicking heterocyclic cores. Pyrazolopyridines are a group of privileged heterocyclic cores in kinase drug discovery, which are present in several inhibitors that have been developed against various cancers...
May 22, 2024: RSC medicinal chemistry
keyword
keyword
56619
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.